BioMarin Pharmaceutical PE Ratio 2006-2021 | BMRN

Current and historical p/e ratio for BioMarin Pharmaceutical (BMRN) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. BioMarin Pharmaceutical PE ratio as of October 15, 2021 is 99.86.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

BioMarin Pharmaceutical PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-15 75.89 17.69
2021-06-30 83.44 $4.29 19.45
2021-03-31 75.51 $4.06 18.60
2020-12-31 87.69 $4.41 19.88
2020-09-30 76.08 $4.37 17.41
2020-06-30 123.34 $0.66 186.88
2020-03-31 84.50 $0.61 138.52
2019-12-31 84.55 $-0.15 0.00
2019-09-30 67.40 $-0.26 0.00
2019-06-30 85.65 $-0.63 0.00
2019-03-31 88.83 $-0.51 0.00
2018-12-31 85.15 $-0.45 0.00
2018-09-30 96.97 $-0.72 0.00
2018-06-30 94.20 $-0.72 0.00
2018-03-31 81.07 $-0.84 0.00
2017-12-31 89.17 $-0.67 0.00
2017-09-30 93.07 $-0.90 0.00
2017-06-30 90.82 $-1.09 0.00
2017-03-31 87.78 $-3.49 0.00
2016-12-31 82.84 $-3.93 0.00
2016-09-30 92.52 $-3.01 0.00
2016-06-30 77.80 $-3.35 0.00
2016-03-31 82.48 $-1.25 0.00
2015-12-31 104.76 $-1.15 0.00
2015-09-30 105.32 $-2.01 0.00
2015-06-30 136.78 $-1.36 0.00
2015-03-31 124.62 $-1.08 0.00
2014-12-31 90.40 $-0.92 0.00
2014-09-30 72.16 $-0.88 0.00
2014-06-30 62.21 $-1.31 0.00
2014-03-31 68.21 $-1.24 0.00
2013-12-31 70.35 $-1.28 0.00
2013-09-30 72.17 $-1.28 0.00
2013-06-30 55.74 $-0.94 0.00
2013-03-31 62.26 $-1.05 0.00
2012-12-31 49.20 $-0.95 0.00
2012-09-30 40.26 $-0.75 0.00
2012-06-30 39.58 $-0.87 0.00
2012-03-31 34.25 $-0.65 0.00
2011-12-31 34.38 $-0.48 0.00
2011-09-30 31.87 $-0.36 0.00
2011-06-30 27.21 $1.48 18.39
2011-03-31 25.13 $1.52 16.53
2010-12-31 26.93 $1.57 17.15
2010-09-30 22.35 $1.73 12.92
2010-06-30 18.96 $0.11 172.36
2010-03-31 23.37 $0.13 179.77
2009-12-31 18.81 $-0.01 0.00
2009-09-30 18.08 $0.15 120.53
2009-06-30 15.61 $0.10 156.10
2009-03-31 12.35 $0.13 95.00
2008-12-31 17.80 $0.28 63.57
2008-09-30 26.49 $0.10 264.90
2008-06-30 28.98 $0.04 724.50
2008-03-31 35.37 $-0.04 0.00
2007-12-31 35.40 $-0.16 0.00
2007-09-30 24.90 $-0.30 0.00
2007-06-30 17.94 $-0.33 0.00
2007-03-31 17.26 $-0.31 0.00
2006-12-31 16.39 $-0.34 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $13.915B $1.860B
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00